Malaria Consortium, Abuja, Nigeria.
Malaria Consortium, London, UK.
Malar J. 2020 Oct 30;19(1):384. doi: 10.1186/s12936-020-03449-5.
Nigeria was among the first African countries to adopt and implement change of treatment policy for severe malaria from quinine to artesunate. Seven years after the policy change health systems readiness and quality of inpatient malaria case-management practices were evaluated in Kano State of Nigeria.
A cross-sectional survey was undertaken in May 2019 at all public hospitals. Data collection comprised hospital assessments, interviews with inpatient health workers and data extraction from medical files for all suspected malaria patients admitted to the paediatric and medical wards in April 2019. Descriptive analyses included 22 hospitals, 154 health workers and 1,807 suspected malaria admissions analysed from malaria test and treat case-management perspective.
73% of hospitals provided malaria microscopy, 27% had rapid diagnostic tests and 23% were unable to perform any parasitological malaria diagnosis. Artemisinin-based combination therapy (ACT) was available at 96% of hospitals, artemether vials at 68% while injectable quinine and artesunate were equally stocked at 59% of hospitals. 32%, 21% and 15% of health workers had been exposed to relevant trainings, guidelines and supervision respectively. 47% of suspected malaria patients were tested while repeat testing was rare (7%). 60% of confirmed severe malaria patients were prescribed artesunate. Only 4% of admitted non-severe test positive cases were treated with ACT, while 76% of test negative patients were prescribed an anti-malarial. Artemether was the most common anti-malarial treatment for non-severe test positive (55%), test negative (43%) and patients not tested for malaria (45%). In all categories of the patients, except for confirmed severe cases, artemether was more commonly prescribed for adults compared to children. 44% of artesunate-treated patients were prescribed ACT follow-on treatment. Overall compliance with test and treat policy for malaria was 13%.
Translation of new treatment policy for severe malaria into inpatient practice is compromised by lack of malaria diagnostics, stock-outs of artesunate and suboptimal health workers' practices. Establishment of the effective supply chain and on-going supportive interventions for health workers accompanied with regular monitoring of the systems readiness and clinical practices are urgently needed.
尼日利亚是首批采用并实施重症疟疾治疗政策从奎宁改为青蒿琥酯的非洲国家之一。政策变更 7 年后,在尼日利亚卡诺州评估了卫生系统准备情况和住院疟疾病例管理实践的质量。
2019 年 5 月,在所有公立医院进行了横断面调查。数据收集包括医院评估、对住院卫生工作者的访谈以及从 2019 年 4 月收治的儿科和内科病房所有疑似疟疾患者的病历中提取数据。描述性分析包括从疟疾检测和治疗病例管理角度分析的 22 家医院、154 名卫生工作者和 1807 例疑似疟疾入院病例。
73%的医院提供疟疾显微镜检查,27%的医院有快速诊断检测,23%的医院无法进行任何寄生虫学疟疾诊断。96%的医院可提供青蒿琥酯为基础的联合治疗药物(ACT),68%的医院有青蒿琥酯注射剂,59%的医院同时储备注射用奎宁和青蒿琥酯。分别有 32%、21%和 15%的卫生工作者接受过相关培训、指南和监督。47%的疑似疟疾患者接受了检测,而重复检测很少(7%)。60%的确诊重症疟疾患者开了青蒿琥酯处方。仅有 4%的入院非重症检测阳性病例接受了 ACT 治疗,而 76%的检测阴性患者开了抗疟药物。在非重症检测阳性(55%)、检测阴性(43%)和未检测疟疾的患者(45%)中,青蒿琥酯是最常见的抗疟药物治疗。在除确诊重症病例外的所有类别患者中,青蒿琥酯更常用于治疗成人而非儿童。44%的青蒿琥酯治疗患者开了 ACT 后续治疗。疟疾检测和治疗政策的总体依从率为 13%。
新的重症疟疾治疗政策转化为住院治疗实践受到缺乏疟疾诊断、青蒿琥酯缺货和卫生工作者做法欠佳的影响。迫切需要建立有效的供应链和对卫生工作者的持续支持性干预措施,并定期监测系统准备情况和临床实践。